ACTU (Actuate Therapeutics) 12-1 Month Momentum %: -64.06% (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ACTU Actuate Therapeutics Inc ACTU
14 GF Score
Price $1.40
View Full Analysis

What is Actuate Therapeutics 12-1 Month Momentum %?

Actuate Therapeutics ACTU -3.11% 14 12-1 Month Momentum % is -64.06% as of Jul. 21, 2026. GuruFocus rates ACTU with a GF Score™ of 14/100. Among 1,358 Biotechnology companies, Actuate Therapeutics ranks worse than 87.11% on this metric.

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-07-21), Actuate Therapeutics's 12-1 Month Momentum % is -64.06%.

The industry rank for Actuate Therapeutics's 12-1 Month Momentum % or its related term are showing as below:

ACTU's 12-1 Month Momentum % is ranked worse than
87.11% of 1358 companies
in the Biotechnology industry
Industry Median: -16.315 vs ACTU: -64.06

Actuate Therapeutics  (NAS:ACTU) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Actuate Therapeutics 12-1 Month Momentum % Related Terms

ACTU vs RNXT, ESLA, APLM: 12-1 Month Momentum % Comparison

For the Biotechnology subindustry, Actuate Therapeutics's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Actuate Therapeutics 12-1 Month Momentum % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actuate Therapeutics's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Actuate Therapeutics's 12-1 Month Momentum % falls into.


ACTU
14GF Score
Actuate Therapeutics Inc ACTU
12-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Actuate Therapeutics  (NAS:ACTU) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 12-1 Month Momentum % →
What does a 12-1 Month Momentum % of -64.06% mean?
Actuate Therapeutics (ACTU) has a 12-1 Month Momentum % of -64.06% as of Jul. 21, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Actuate Therapeutics and its competitors. According to the industry distribution chart, Actuate Therapeutics ranks #1183 out of 1358 companies in the Biotechnology industry, placing it in the top 87.1%.
Is Actuate Therapeutics' 12-1 Month Momentum % too high?
Actuate Therapeutics' current 12-1 Month Momentum % is -64.06%. Based on the distribution chart, Actuate Therapeutics ranks #1183 out of 1358 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Actuate Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Actuate Therapeutics' 12-1 Month Momentum % compare to RNXT and ESLA?
According to the Biotechnology industry distribution chart, Actuate Therapeutics ranks #1183 out of 1358 companies for 12-1 Month Momentum %. This places Actuate Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Biotechnology company?
A good 12-1 Month Momentum % depends on the Biotechnology industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Actuate Therapeutics and its competitors. Actuate Therapeutics's current 12-1 Month Momentum % is -64.06%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actuate Therapeutics stock overvalued right now?
Actuate Therapeutics (ACTU) has a current 12-1 Month Momentum % of -64.06%. The current 12-1 Month Momentum % is -64.06%. Actuate Therapeutics' overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Actuate Therapeutics (ACTU), the current 12-1 Month Momentum % is -64.06% as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Actuate Therapeutics Business Description

Address 1751 River Run, Suite 400, Fort Worth, TX, USA, 76107
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
14GF Score

Get the complete analysis for ACTU

12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.40
Price